uniQure NV (QURE) Covered Calls

uniQure NV is engaged in the field of gene therapy and has developed a gene therapy product to receive regulatory approval in the European Union.

You can sell covered calls on uniQure NV to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for QURE (prices last updated Wed 4:16 PM ET):

uniQure NV (QURE) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
39.35 +0.94 33.00 39.80 349K - 1.4B
Covered Calls For uniQure NV (QURE)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
Mar 15 40 2.20 37.60 5.9% 89.7%
Apr 18 40 3.60 36.20 9.9% 62.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

uniQure NV engages in the discovery, development, and commercialization of gene therapies. Its core gene therapies include AMT-060 for the treatment of hemophilia B; preclinical S100A1 therapeutic for the treatment of congestive heart failure; and Glybera a gene therapy that is designed to restore the LPL enzyme activity required to enable the processing, or clearance, of fat-carrying chylomicron particles formed in the intestine after a fat-containing meal. uniQure was founded on January 9, 2012 and is headquartered in Amsterdam, Netherlands.